Oculis Holding AG
NasdaqGM:OCS Stock Report
Oculis Holding Future Growth
Future criteria checks 2/6 Oculis Holding's earnings are forecast to decline at 2% per annum while its annual revenue is expected to grow at 62.8% per year. EPS is expected to grow by 4.8% per annum. Return on equity is forecast to be -1.3% in 3 years.
Key information
-2.0%
Earnings growth rate
Pharmaceuticals earnings growth 23.8% Revenue growth rate 62.8% Future return on equity -1.3% Analyst coverage Good
Last updated 11 Nov 2024
Recent future growth updates
Show all updates
Oculis: Lack Of Coverage Only Real Risk For This Solid Company Nov 04
Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer Oct 02
Oculis Holding AG Appoints Sharon Klier as Chief Development Officer Aug 15 Oculis Holding AG to Report Q2, 2024 Results on Aug 14, 2024
Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy Jun 13
Oculis Holding AG Announces Board and Committee Appointments May 30
First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023) May 09 Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million. May 09
Oculis Holding AG, Annual General Meeting, May 29, 2024 May 01
Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million. Apr 24
Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million. Apr 12
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development Apr 10
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Apr 09
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 20
New major risk - Revenue and earnings growth Mar 20
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Dec 21
Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema Dec 19
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease Dec 08
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 17 Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors Nov 17
Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress Oct 11
Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema Oct 06
New major risk - Revenue and earnings growth Oct 01
Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer Sep 12
Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022) Sep 02
Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops Aug 09
Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases Jun 28
High number of new and inexperienced directors Mar 30
Earnings and Revenue Growth Forecasts NasdaqGM:OCS - Analysts future estimates and past financials data (CHF Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts 12/31/2026 41 -85 N/A N/A 3 12/31/2025 21 -70 N/A N/A 3 12/31/2024 1 -77 N/A N/A 6 9/30/2024 1 -70 N/A N/A N/A 6/30/2024 1 -67 -52 -52 N/A 3/31/2024 1 -59 -51 -51 N/A 12/31/2023 1 -89 -54 -54 N/A 9/30/2023 1 -85 -49 -47 N/A 6/30/2023 1 -78 -44 -42 N/A 3/31/2023 1 -75 -38 -35 N/A 12/31/2022 1 -39 -29 -25 N/A 9/30/2022 1 -35 -24 -22 N/A 12/31/2021 1 -19 -14 -14 N/A 12/31/2020 1 -15 -12 -12 N/A
Show more
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OCS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OCS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OCS's revenue (62.8% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: OCS's revenue (62.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OCS is forecast to be unprofitable in 3 years.
Discover growth companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}